LCM
FPRX

Laurion Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Laurion Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,800
Closed -$210K – 1975
2017
Q1 		$210K Buy
+5,800
New +$256K ﹤0.01% 1178
2016
Q2 		– Sell
-15,900
Closed -$646K – 1100
2016
Q1 		$646K Buy
+15,900
New +$546K 0.01% 489

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Laurion Capital Management's FPRX Position: Q2 2017 in Review

Laurion Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 5,800 shares — an estimated $210K sold.

Laurion Capital Management first reported a position in FPRX in Q1 2016 and held it in 2 quarters. The position peaked at $646K in Q1 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Laurion Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Laurion Capital Management sold 5,800 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $210K.
  • Laurion Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • Laurion Capital Management's Five Prime Therapeutics, Inc. position peaked at $646K in Q1 2016.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Laurion Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.